📊 BICX Key Takeaways
Is BioCorRx Inc. (BICX) a Good Investment?
BioCorRx is in severe financial distress with negative stockholders' equity of -$13.5M, indicating the company is technically insolvent. Revenue has collapsed 92.8% year-over-year to just $948.4K while operating losses of -$4.3M persist, demonstrating a non-viable business model. With only $287.7K in cash, a current ratio of 0.10x, and negative operating cash flow of -$1.5M, the company faces imminent liquidity crisis and potential bankruptcy.
BioCorRx's fundamentals are extremely weak, with revenue down 92.8% year over year, deeply negative operating and net margins, and continued cash burn. The balance sheet is severely stressed, with negative equity, a 0.10x current ratio, and very limited cash, which raises substantial going-concern and dilution/refinancing risk. While gross margin remains positive and the company carries no long-term debt, those positives are far outweighed by collapsing scale and poor financial health.
Why Buy BioCorRx Inc. Stock? BICX Key Strengths
- Gross margin of 67.9% indicates products/services retain pricing power when sold
- Zero long-term debt eliminates debt service obligations
- Specialty outpatient facilities sector has structural demand drivers
- Positive gross margin of 67.9% indicates the core offering can generate gross profit
- No long-term debt reduces fixed long-duration leverage risk
- Capital-light profile with no reported capital expenditures
BICX Stock Risks: BioCorRx Inc. Investment Risks
- Negative stockholders' equity of -$13.5M represents technical insolvency and shareholder value destruction
- Revenue decline of 92.8% YoY indicates loss of core business or market rejection
- Critical liquidity crisis: $287.7K cash against $20.3M liabilities with current ratio of 0.10x
- Negative operating cash flow of -$1.5M with minimal cash reserves means days to months of runway
- Operating losses of -$4.3M on $948.4K revenue indicates fundamentally broken unit economics
- No insider buying activity in last 90 days suggests management lacks confidence
- Revenue collapsed 92.8% year over year, indicating severe deterioration in business scale
- Liquidity is critically weak with only $287.69K cash and a 0.10x current ratio
- Negative stockholders' equity of $13.48M and ongoing operating losses increase solvency and financing risk
Key Metrics to Watch
- Cash balance and runway to insolvency
- Revenue stabilization or further deterioration
- Operating cash flow trajectory and burn rate
- Debt covenant compliance and bankruptcy filing risk
- Revenue stabilization or return to year-over-year growth
- Operating cash burn and near-term liquidity/current liabilities coverage
BioCorRx Inc. (BICX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BICX Profit Margin, ROE & Profitability Analysis
BICX vs Services Sector: How BioCorRx Inc. Compares
How BioCorRx Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioCorRx Inc. Stock Overvalued? BICX Valuation Analysis 2026
Based on fundamental analysis, BioCorRx Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioCorRx Inc. Balance Sheet: BICX Debt, Cash & Liquidity
BICX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioCorRx Inc.'s revenue has grown significantly by 550% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.49 indicates the company is currently unprofitable.
BICX Revenue Growth, EPS Growth & YoY Performance
BICX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.5M | $-0.11 |
| Q2 2025 | $4.0K | -$1.2M | $-0.07 |
| Q3 2024 | N/A | -$867.3K | N/A |
| Q2 2024 | $4.0K | -$923.5K | N/A |
| Q1 2024 | $3.6K | -$841.4K | N/A |
| Q3 2023 | $10.1K | -$867.3K | N/A |
| Q2 2023 | $16.0K | -$923.5K | N/A |
| Q1 2023 | $20.5K | -$945.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioCorRx Inc. Dividends, Buybacks & Capital Allocation
BICX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioCorRx Inc. (CIK: 0001443863)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BICX
What is the AI rating for BICX?
BioCorRx Inc. (BICX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BICX's key strengths?
Claude: Gross margin of 67.9% indicates products/services retain pricing power when sold. Zero long-term debt eliminates debt service obligations. ChatGPT: Positive gross margin of 67.9% indicates the core offering can generate gross profit. No long-term debt reduces fixed long-duration leverage risk.
What are the risks of investing in BICX?
Claude: Negative stockholders' equity of -$13.5M represents technical insolvency and shareholder value destruction. Revenue decline of 92.8% YoY indicates loss of core business or market rejection. ChatGPT: Revenue collapsed 92.8% year over year, indicating severe deterioration in business scale. Liquidity is critically weak with only $287.69K cash and a 0.10x current ratio.
What is BICX's revenue and growth?
BioCorRx Inc. reported revenue of $948.4K.
Does BICX pay dividends?
BioCorRx Inc. does not currently pay dividends.
Where can I find BICX SEC filings?
Official SEC filings for BioCorRx Inc. (CIK: 0001443863) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BICX's EPS?
BioCorRx Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BICX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioCorRx Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BICX stock overvalued or undervalued?
Valuation metrics for BICX: ROE of N/A (sector avg: 16%), net margin of -421.0% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BICX stock in 2026?
Our dual AI analysis gives BioCorRx Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BICX's free cash flow?
BioCorRx Inc.'s operating cash flow is $-1.5M, with capital expenditures of $0.0. FCF margin is -153.0%.
How does BICX compare to other Services stocks?
Vs Services sector averages: Net margin -421.0% (avg: 10%), ROE N/A (avg: 16%), current ratio 0.10 (avg: 1.5).